An interventional study of App for in-bed conditioning exercises and Usual care in Spine Degeneration, Hip Arthritis and Knee Osteoarthritis, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Yale University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 272nd largest by planned enrollment of the 691 interventional ones that give a count, is one of 37 that started in 2025, is one of 376 with no phase, reaches primary completion later than 46 of the 151 other live ones, and was the 715th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
VA Office of Research and Development · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 37 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 566 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 4 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effectiveness of a mobile application in improving postoperative rehabilitation outcomes among patients undergoing orthopedic surgery.
The study aims to assess the effectiveness of a mobile app-based tool in improving conditioning, mobility, and physical therapy performance among patients recovering from orthopedic surgery, particularly hip fracture fixation, spinal fusion, and total knee/hip arthroplasty. The app sets reminders for in-bed conditioning exercises, with difficulty levels adjusted based on patient feedback. The prospective, single-arm pilot study will enroll patients over 65 years old with adequate cognitive status and a mobile phone. Patient performance on the app, satisfaction metrics, and physical therapy outcomes will be evaluated, along with feedback from physical therapists. The study is conducted through the Yale New Haven Health System, with plans to enroll 15 patients initially and subsequently expand to a randomized controlled trial with 50 participants in each arm. The goal is to improve outcomes in this population, characterized by poor mobility, morbidity, and mortality rates, by supplementing inpatient rehabilitation with targeted, app-prompted exercises.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe physical impairment:
Unstable medical conditions:
Open wounds or surgical incisions
Vulnerable populations
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Post-operative usual care where patients will receive standard care plus the use of a tool.
Device: App for in-bed conditioning exercises · Other: Usual care
Post-operative usual care where patients will receive standard care alone.
Other: Usual care
Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients
All participants will receive usual care in the post-operative setting.
Change in patient performance during physical therapy (PT)
Patient performance during physical therapy will be assessed using The Activity Measure for Post-Acute Care (AMPAC). The AMPAC score is a comprehensive assessment tool used to evaluate a patient's functional abilities in various domains, including mobility, daily activities, and social interaction. Total score range from 6-24 with higher scores indicating the participant is able to independently perform all activities.
Time frame: Initial (postoperative day 1) and Final PT Visit (at discharge approximately day 3-5 postoperative)
Patient-reported satisfaction metrics
Patients will be surveyed at the end of their intervention using 18 Likert scale (1 to 10), with 10 questions pertaining to their patient care experience, and 8 questions pertaining to their experience using the StrongRx tool. Survey will be piloted to ensure feasibility and ease of completion. Total score range 18-180 with higher scores indicating higher satisfaction.
Time frame: at postoperative day 3-5
Length of stay
Length of hospital stay serves as a secondary outcome to assess the impact of the intervention on healthcare resource utilization and patient recovery. A shorter length of stay may indicate improved outcomes and efficiency of care delivery, potentially resulting from enhanced rehabilitation efforts facilitated by the tool.
Time frame: an average of 3-5 days
Postoperative VAS scores
Pain management is a critical aspect of postoperative care, and VAS scores provide a reliable measure of patients' subjective pain levels. Scores will range from 0 (No Pain) to 10 (Worse Pain Possible), with emotion icons to help patients identify which pain level most closely corresponds to their current level. Higher scores indicating more pain.
Time frame: immediately postoperative and day of last admission, up to 5 days
Patient performance on the app
Evaluation of patient performance on the StrongRx app includes tracking points obtained, levels achieved, and exercise sets completed per day. Number of sets completed for each exercise will accrue 1 point for the patient. There will be 3 levels of ease that that will be user directed based on whether the patient is able to easily complete the set. For each level obtained, the points will get a multiplier (1x, 2x, 3x), which corresponds to the multiple of increased repetitions of the exercise. Higher scores indicate more exercises completed.
Time frame: an average of 3-5 days
Patient compliance with prescribed exercises
Compliance with prescribed exercises serves to assess the extent to which patients adhere to the recommended rehabilitation regimen. Defined as the number of missed exercises and missed sets.
Time frame: an average of 3-5 days
Physical therapist feedback on app setup assistance, patient interaction, and suggestions for improvement to assess feasibility
This data will be gathered as a survey for the physical therapists working on the orthopedics floor at our study site. The survey will include questions regarding the integration of the tool within their workflow, patient interaction, performance during their standardized therapy encounters, and overall recommendation. These will be based on Likert Scale (1 to 10). Total score range 5-50, higher scores indicate more satisfaction. There are also free text questions related to facilitators and barriers.
Time frame: up to 120 days
Adverse Events
Monitoring adverse events serves as a secondary outcome to evaluate the safety profile of the intervention. Tracking minor events such as hematoma, wound dehiscence, and urinary tract infections, as well as severe events including surgical site infections and pulmonary emboli, provides comprehensive data on potential risks associated with the intervention.
Time frame: Up to 90 Days
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 17 months is close to that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.